Human glioblastoma multiforme: P53 reactivation by a novel MDM2 inhibitor

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Costa, Barbara ^a   Bendinelli, Sara ^a   Gabelloni, Pamela ^a   Da Pozzo, Eleonora ^a   Daniele, Simona ^a   Scatena, Fabrizio ^b   Vanacore, Renato ^b   Campiglia, Pietro ^c   Bertamino, Alessia ^d   Gomez Monterrey, Isabel ^d   Sorriento, Daniela ^d   Del Giudice, Carmine ^d   Iaccarino, Guido ^c,e   Novellino, Ettore ^d   Martini, Claudia ^a  

^a UNIVERSITY OF PISA   (Italy)

^b CISANELLO HOSPITAL   (Italy)

^c UNIVERSITY OF SALERNO   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e IRCCS MULTIMEDICA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ISA 27; PROTEIN P53; TEMOZOLOMIDE; UNCLASSIFIED DRUG; 6-(4-CHLOROBENZYL)-1H-SPIRO(IMIDAZO(1,5-C)THIAZOLE-3,3′-INDOLINE)-2′,5,7(6H,7AH)-TRIONE; INDOLE DERIVATIVE; MDM2 PROTEIN, HUMAN; MOLECULAR LIBRARY; PROTEIN BINDING; PROTEIN MDM2; SPIRO COMPOUND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG EFFECT; DRUG POTENTIATION; DRUG STRUCTURE; GENE TARGETING; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; TUMOR SUPPRESSOR GENE; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BRAIN NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IC50; METABOLISM; MOLECULAR LIBRARY; NUDE MOUSE; PATHOLOGY; PHARMACOLOGY; SIGNAL TRANSDUCTION; TUMOR VOLUME;

MURINAE; MUS MUSCULUS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; MICE; MICE, INBRED BALB C; MICE, NUDE; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MDM2; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; SPIRO COMPOUNDS; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899051588     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072281     Document Type: Article

References (54)

1. Liu J, Ma Q, Zhang M, Wang X, Zhang D, et al. (2012) Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: Evidence from a systematic review and meta-analysis. Eur J Cancer 48: 2328-2338.
2. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, et al. (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21: 2683-2710.
3. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, et al. (2004) Genetic pathways to glioblastoma: a population-based study. Cancer Res 64: 6892-6899.
4. Conrad CA, Milosavljevic VP, Yung WK (1995) Advances in chemotherapy for brain tumors. Neurol Clin 13: 795-812.
5. Levin VA, Leibel SA, Gutin PH (2001) Neoplasms of the central nervous system. In: De Vita Jr VT, Hellman S, Rosenberg SA, editors. Cancer principles of oncology. Philadelphia: Lippincott-Raven. 2100-2161.
6. Desjardins A, Rich IN, Quinn JA, Vredenburgh J, Gururangan S, et al. (2005) Chemotherapy and novel therapeutic approaches in malignant glioma. Front Biosci 10: 2645-2668.
7. Hess KR, Broglio KR, Bondy ML (2004) Adult glioma incidence trends in the United States, 1977-2000. Cancer 101: 2293-2299.
8. Nagasawa DT, Chow F, Yew A, Kim W, Cremer N, et al. (2012) Temozolomide and other potential agents for the treatment of glioblastoma multiforme. Neurosurg Clin N Am. 23: 307-322.
9. Ohgaki H, Kleihues P (2009) Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci 100: 2235-2241.
10. Cerami E, Demir E, Schultz N, Taylor BS, Sander C (2010) Automated network analysis identifies core pathways in glioblastoma. PLoS One 5: e8918.
11. He J, Reifenberger G, Liu L, Collins VP, James CD (1994) Analysis of glioma cell lines for amplification and overexpression of MDM2. Genes Chrom Cancer 11: 91-96.
12. Freedman DA, Wu L, Levine AJ (1999) Functions of the MDM2 oncoprotein. Cell Mol Life Sci 55: 96-107.
13. Halatsch ME, Schmidt U, Unterberg A, Vougioukas VI (2006) Uniform MDM2 overexpression in a panel of glioblastoma multiforme cell lines with divergent EGFR and p53 expression status. Anticancer Res 26: 4191-4194.
14. Li C, Shen J, Wei X, Xie C, Lu W (2012) Targeted delivery of a novel palmitylated D-peptide for antiglioblastoma molecular therapy. J Drug Target 20: 264-271.
15. Wang B, Fang L, Zhao H, Xiang T, Wang D (2012) MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells. Acta Biochim Biophys Sin (Shanghai). 44: 685-691.
16. Henze J, Mühlenberg T, Simon S, Grabellus F, Rubin B, et al. (2012) p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors. PLoS One 7: e37776.
17. Shangary S, Wang S (2009) Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 49: 223-241.
18. Vu BT, Vassilev L (2011) Small-molecule inhibitors of the p53-MDM2 interaction. Curr Top Microbiol Immunol 348: 151-172.
19. Azmi AS, Aboukameel A, Banerjee S, Wang Z, Mohammad M, et al. (2010) MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function. Eur J Cancer 46: 1122-1131.
20. Sonnemann J, Palani CD, Wittig S, Becker S, Eichhorn F, et al. (2011) Anticancer effects of the p53 activator nutlin-3 in Ewing's sarcoma cells. Eur J Cancer 47: 1432-1441.
21. Ghassemifar S, Mendrysa SM. (2012) MDM2 antagonism by nutlin-3 induces death in human medulloblastoma cells. Neurosci Lett. 513: 106-110.
22. Chappell WH, Lehmann BD, Terrian DM, Abrams SL, Steelman LS, et al. (2012) p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3. Cell Cycle 11: 4579-4588.
23. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 303: 844-888.
24. Liu M, Li C, Pazgier M, Li C, Mao Y, et al. (2010) D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms. Proc Natl Acad Sci U S A. 107: 14321-14326.
25. Villalonga-Planells R, Coll-Mulet L, Martínez-Soler F, Castano E, Acebes JJ, et al. (2011) Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme. PLoS One 6: e18588.
26. Gomez-Monterrey I, Bertamino A, Porta A, Carotenuto A, Musella S, et al. (2010) Identification of the Spiro(oxindole-3,39-thiazolidine)-Based Derivatives as Potential p53 Activity Modulators. J Med Chem 53: 8319-8329.
27. Boyum A (1968) Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl 97: 77-89.
28. Lee SK, Kim YC, Song SB, Kim YS (2010) Stabilization and translocation of p53 to mitochondria is linked to Bax translocation to mitochondria in simvastatin-induced apoptosis. Biochem Biophys Res Commun. 391: 1592-1597.
29. Sosin AM, Burger AM, Siddiqi A, Abrams J, Mohammad RM, et al. (2012) HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas. J Hematol Oncol. 5, 57.
30. Vaseva AV, Yallowitz AR, Marchenko ND, Xu S, Moll UM (2011) Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors. Cell Death Dis. 2: e156.
31. Vandesompele J, De Paepe A, Speleman F (2002) Elimination of primer-dimer artifacts and genomic coamplification using a two-step SYBR green I real-time RT-PCR. Anal Biochem 303: 95-98.
32. Chelli B, Lena A, Vanacore R, Da Pozzo E, Costa B, et al. (2004) Peripheral benzodiazepine receptor ligands: mitochondrial transmembrane potential depolarization and apoptosis induction in rat C6 glioma cells. Biochem Pharmacol 68: 125-134.
33. Ruan S, Okcu MF, Pong RC, Andreeff M, Levin V, et al. (1999) Attenuation of WAF1/Cip1 expression by an antisense adenovirus expression vector sensitizes glioblastoma cells to apoptosis induced by chemotherapeutic agents 1,3-bis(2- chloroethyl)-1-nitrosourea and cisplatin. Clin Cancer Res 5: 197-202.
34. Chelli B, Rossi L, Da Pozzo E, Costa B, Spinetti F, et al. (2005) PIGA (N,N-Din- butyl-5-chloro-2-(4-chlorophenyl)indol-3-ylglyoxylamide), a new mitochondrial benzodiazepine-receptor ligand, induces apoptosis in C6 glioma cells. Chembiochem 6: 1082-1088.
35. Dimri GP, Lee X, Basile G, Acosta M, Scott G, et al. (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 92: 9363-9367.
36. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 7: 248-254.
37. Sorriento D, Campanile A, Santulli G, Leggiero E, Pastore L, et al. (2009) A new synthetic protein, TAT-RH, inhibits tumor growth through the regulation of NFkappaB activity. Mol Cancer 8, 97.
38. Santulli G, Cipolletta E, Sorriento D, Del Giudice C, Anastasio A, et al. (2012) CaMK4 Gene Deletion Induces Hypertension. J Am Heart Assoc 1: e001081.
39. Berenbaum MC (1989) What is synergy? Pharmacol Rev. 41: 93-141.
40. Tallarida RJ (1992) Statistical analysis of drug combinations for synergism. Pain. 49: 93-97.
41. Review. Erratum in: Pain 1993 53: 365.
42. Tallarida RJ, Stone DJ Jr, McCary JD, Raffa RB (1999) Response surface analysis of synergism between morphine and clonidine. J Pharmacol Exp Ther. 289: 8-13.
43. Erratum in: J Pharmacol Exp Ther 1999 289: 1184.
44. Tallarida RJ (2002) The interaction index: a measure of drug synergism. Pain. 98: 163-168.
45. Wang CC, Liao YP, Mischel PS, Iwamoto KS, Cacalano NA, et al. (2006) HDJ- 2 as a target for radiosensitization of glioblastoma multiforme cells by the farnesyltransferase inhibitor R115777 and the role of the p53/p21 pathway. Cancer Res 66: 6756-6762.
46. Zhao P, Wang D, Gao Y, Yang Z, Li X (1998) Overexpression of MDM2, p53, and NCAM proteins in human radiation-induced skin ulcers. J Environ Pathol Toxicol Oncol 17: 125-127.
47. Kondo S, Barnett GH, Hara H, Morimura T, Takeuchi J (1995) MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis. Oncogene 10: 2001-2006.
48. Mayo LD, Dixon JE, Durden DL, Tonks NK, Donner DB (2002) PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem 277: 5484-5489.
49. Tabernero J, Dirix L, Schöffski P, Cervantes A, Lopez-Martin JA, et al. (2011) A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors. Clin Cancer Res 17: 6313-6321.
50. Secchiero P, Barbarotto E, Tiribelli M, Zerbinati C, di Iasio MG, et al. (2006) Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood 107: 4122-4129.
51. Stühmer T, Chatterjee M, Hildebrandt M, Herrmann P, Gollasch H, et al. (2005) Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood 106: 3609-3617.
52. Kojima K, Konopleva M, Samudio IJ, Shikami M, Cabreira-Hansen M, et al. (2005) MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 106: 3150-3159.
53. Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, et al. (2006) Smallmolecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A 103: 1888-1893.
54. Shangary S, Ding K, Qiu S, Nikolovska-Coleska Z, Bauer JA, et al. (2008) Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21- mediated cell cycle arrest and selective cell death in colon cancer. Mol Cancer Ther 7: 1533-1542.